Born: 1950 Title: Member of the Board since 2018, Chairman of the Board since 2021. Former CEO of Medivir AB.
Education: PhD at Uppsala University.
Background: Senior positions in major pharmaceutical and biotech companies for over 30 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public, multibillion dollar company. In the 1990s, he held senior positions at Astra AB, prior to which he was a Professor of Organic Chemistry at Uppsala University.
Other directorships: Chairman of the Boards of Annexin Pharmaceuticals AB and SynAct Pharma AB. Member of the Boards of Active Biotech and InDex Pharmaceuticals AB.
Shares in Medivir: 400,000 class B shares.
Born: 1956 Title: Member of the Board since 2018.
Education: Ph.D. in Genetics from Umeå University.
Background: Extensive experience of pharmaceutical and commercial development in senior positions with both biotech and pharmaceutical companies, such as KabiGen AB, Symbicom AB, AstraZeneca, and Biovitrum AB, and as CEO of Arexis AB. Responsible for Industrifonden’s life science operations from 2008 to 2016. He has held seats on the Boards of over 30 companies and is also a co-founder of two pharmaceutical development companies.
Other directorships: Member of the Board of InDex Pharmaceuticals AB. Chairman of the Boards of Cinclus Pharma Holding AB, Ignitus AB and Sixera Pharma AB.
Shares in Medivir: 20,000 class B shares.
Born: 1961.
Title: Member of the Board since 2022.
Education: Degree of Bachelor of Science in Accounting and Finance from Gothenburg University.
Background: Anette is currently CFO of XBrane Biopharma AB. She has a solid background in auditing with former operational assignments in Astrazeneca, Getinge and Sobi.
Other directorships: Chairperson of the Board of Nanolyze AB.
Shares in Medivir: 0.
Born: 1979. Title: Member of the Board since 2021.
Education: Ph.D. Medical Sciences, Karolinska Institutet.
Background: CFO at Egetis Therapeutics AB. Former CFO at PledPharma and among others responsible for the listing of the company at Nasdaq Stockholm Main Market and former CEO at Medivir AB. Prior to that Investment Manager & Controller at Industrifonden and healthcare analyst at Pareto Securities and Öhman Fondkommission. Started his career as a researcher at Karolinska Institutet and later at the pharmaceutical companies Biolipox and Orexo.
Other directorships: Board member of Mahshid Advisors.
Shares in Medivir: 25,000.
Warrants in Medivir: 300,000.
Born: 1945. Title: Member of the Board since 2017.
Education: Professor of Tumour Biology at Uppsala University, the Faculty of Medicine, since 1986.
Background: Dean of the Faculty of Medicine at Uppsala University, 1996-2002, and Vice-Rector of Medicine and Pharmacy, 1999-2002. Chairman of the research board of the Swedish Cancer Society, 2003-2013. He has published over 300 papers in scientific journals, primarily on the mechanisms governing the uncontrolled growth of cancer cells. Member of the Royal Swedish Academy of Sciences, the European Molecular Biology Organisation, and the European Academy of Cancer Sciences.
Other directorships: Member of the board of several advisory groups for medical research financing.
Shares in Medivir: 16,000 class B shares.